- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01253733
MD2Me - Texting to Promote Chronic Disease Management
TAHLC - Texting to Promote Adolescent Health Liaisons and Chronic Disease Management
Study Overview
Status
Intervention / Treatment
Detailed Description
The MD2Me study (or also known as TAHLC), sponsored by the National Institutes of Health is a 2-year randomized controlled trial to develop and test a text message and Internet based intervention among adolescents and young adults with cystic fibrosis, type 1 diabetes, or inflammatory bowel disease. Adolescents and young adults have been a difficult population to engage in healthcare. It is estimated that 1 in 5 adolescents do not get the healthcare they need. Interventions must address how the healthcare system can engage adolescents with chronic disease and provide opportunities to discuss health-related matters and improve disease outcomes.
This study will help fill multiple gaps in the literature by exploring the utility of a push AND pull SMS texting-based application for chronic disease management among youth. Based on social cognitive theory, the intervention will use accessible technology to promote disease management among adolescents with chronic disease as they transition to adult care. The popularity and usage of SMS already demonstrated by adolescents suggests notable promise for the SMS-based TAHLC program to promote chronic disease self-management and healthcare engagement with substantial positive impacts on health among youth with chronic disease.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ages 14 - 22 years
- have cystic fibrosis, type 1 diabetes, or inflammatory bowel disease for at least 6 months
- have access to the internet
- speak English
- has a parent that speaks English or Spanish (if primary participant is under 18)
- willingness to attend assessment visits
Exclusion Criteria:
- pregnant or have children
- have a history of substance abuse or other psychiatric disorder that would impair compliance with study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SMS and Internet
The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
|
The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently.
The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
|
|
No Intervention: Control
The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health related self-efficacy
Time Frame: 8 months
|
The primary aim of the study will be to develop and test the effect of a texting intervention TAHLC on health-related self-efficacy and frequency of adolescent-conducted healthcare interactions over the study period of 8 months.
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health knowledge
Time Frame: 8 months
|
Disease health knowledge
|
8 months
|
|
Health literacy
Time Frame: 8 months
|
Health literacy
|
8 months
|
|
Quality of Life
Time Frame: 8 Months
|
Quality of life including depression, self-esteem, and social support will be assessed.
|
8 Months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeannie Huang, MD, MPH, University of California, San Diego
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Lung Diseases
- Endocrine System Diseases
- Disease Attributes
- Gastrointestinal Diseases
- Infant, Newborn, Diseases
- Diabetes Mellitus
- Genetic Diseases, Inborn
- Gastroenteritis
- Pancreatic Diseases
- Fibrosis
- Diabetes Mellitus, Type 1
- Inflammatory Bowel Diseases
- Chronic Disease
- Cystic Fibrosis
- Intestinal Diseases
Other Study ID Numbers
- 091146
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Lund UniversityEnrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 DiabetesSweden
-
Immunocore LtdNot yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's Hospital...RecruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes MellitusIraq, Pakistan
-
GentiBio, IncRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes (T1D)United States
-
Stanford UniversityUniversity College Dublin; The Leona M. and Harry B. Helmsley Charitable TrustNot yet recruitingType 1 Diabetes (T1D) | Type 1 Diabetes Mellitus (T1DM) | Exercise Physiology | Type 1 Diabetes MellitisUnited States
-
Dasman Diabetes InstituteRecruitingType 1 Diabetes (T1D) | Type 1 Diabetes Mellitus (T1DM)Kuwait
-
Superior UniversityActive, not recruitingType 2 Diabetes Mellitus 1Pakistan
-
Insulet CorporationNot yet recruitingType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes (DM)New Zealand
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland